Table 2.
Effect of conditioning regimen intensity on disease-free survival, relapse, nonrelapse mortality, and survival
| Outcome | No. of events/evaluable | HR (95% CI) | P |
|---|---|---|---|
| Disease-free survival* | |||
| Age, 18-54 y | |||
| Myeloablative | 183/379 | 1.00 | |
| Reduced intensity | 184/306 | 1.34 (1.08-1.65) | .007 |
| Age, 55-70 y | |||
| Myeloablative | 87/144 | 1.00 | |
| Reduced intensity | 295/489 | 0.97 (0.76-1.24) | .83 |
| Relapse† | |||
| Age, 18-54 y | |||
| Myeloablative | 122/379 | 1.00 | |
| Reduced intensity | 140/306 | 1.51 (1.17-1.94) | .001 |
| Age, 55-70 y | |||
| Myeloablative | 43/144 | 1.00 | |
| Reduced intensity | 201/489 | 1.32 (0.94-1.84) | .11 |
| Nonrelapse mortality‡ | |||
| Age, 18-54 y | |||
| Myeloablative | 61/379 | 1.00 | |
| Reduced intensity | 44/306 | 0.98 (0.66-1.45) | .92 |
| Age, 55-70 y | |||
| Myeloablative | 44/144 | 1.00 | |
| Reduced intensity | 94/489 | 0.64 (0.44-0.92) | .02 |
| Overall survival§ | |||
| Age, 18-54 y | |||
| Myeloablative | 154/381 | 1.00 | |
| Reduced intensity | 138/308 | 1.13 (0.90-1.43) | .30 |
| Age, 55-70 y | |||
| Myeloablative | 82/145 | 1.00 | |
| Reduced intensity | 267/491 | 0.86 (0.67-1.32) | .25 |
Lower disease-free survival for patients with comorbidity score ≥3 compared with ≤2 (HR, 1.21; 95% CI, 1.05-1.40; P = .001) and high disease risk index compared with low disease risk index (HR, 2.04; 95% CI, 1.33-3.14; P = .001) and intermediate disease risk index (HR, 2.03; 95% CI, 1.74-2.37; P < .001). Graft type was not associated with an increased risk of disease-free survival (HR, 0.93 95% CI, 0.80-1.08; P = .34).
Higher relapse for patients with high disease risk index (HR, 2.45; 95% CI, 1.42-4.24; P = .001). Relapse was lower for patients with MDS compared with AML (HR, 0.68; 95% CI, 0.52-0.89; P = .004) and transplant of peripheral blood compared with bone marrow (HR, 0.82; 95% CI, 0.68-0.98; P = .03). Comorbidity score ≥3 was not associated with an increased risk of relapse (HR, 1.06; 95% CI, 0.89-1.27; P = .51).
Higher nonrelapse mortality for patients with comorbidity score ≥3 compared with ≤2 (HR, 1.59; 95% CI, 1.23-2.07; P = .0005) and high disease risk index compared with intermediate disease risk index (HR, 1.80; 95% CI, 1.37-2.37; P < .0001).
Lower overall survival for patients with comorbidity score ≥3 compared with ≤2 (HR, 1.27; 95% CI, 1.08-1.49; P = .003), CMV seropositivity (HR, 1.22; 95% CI, 1.02-1.45; P = .03), AML compared with ALL (HR, 1.40; 95% CI, 1.13-1.85; P = .002), and high disease risk index compared with low disease risk index (HR, 2.37; 95% CI, 1.42-3.94; P = .001) and intermediate disease risk index (HR, 2.00; 95% CI, 1.70-2.36; P < .001).